Navigation Links
A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
Date:8/30/2007

urope, 26 sites are planned and recruitment has commenced at UZ Leuven Gynaecological Oncology in Leuven, Belgium.

The trial is studying the safety and effectiveness of the drug phenoxodiol, which has not yet been approved for marketing by the FDA, when used in combination with weekly doses of the chemotherapy drug, carboplatin. The trial will consist of two double blind treatment arms. Patients in one trial arm will receive weekly carboplatin and phenoxodiol. Patients in the other trial arm will also receive weekly carboplatin, but a placebo will be substituted for phenoxodiol. Neither patients, nor their doctors will know to which trial arm the patients are randomized.

A change from receiving carboplatin (or cisplatin) every two to three weeks to a weekly carboplatin regimen has been reported to provide a tumor response in some patients with recurrent ovarian cancer.(1) In addition to learning more about the safety and efficacy of phenoxodiol, researchers will learn more about the efficacy of weekly carboplatin.

In laboratory studies using animal models of cancer and human cell lines, phenoxodiol was shown to reverse chemoresistance to standard chemotherapies, including platinum drugs, taxanes, gemcitabine, topotecan and doxorubicin. The ability of phenoxodiol to reverse multi-drug resistance is thought to be due to its disruption of several key targets specific to tumor cell biochemistry.

In a prior Phase II clinical trial, phenoxodiol was tested in combination with either cisplatin or paclitaxel. Twenty one patients with late stage ovarian cancer that had become refractory to platinum (cisplatin or carboplatin) and 19 patients that had become resistant to paclitaxel therapy, following multiple courses of chemotherapy, were treated with phenoxodiol and cisplatin or phenoxodiol and paclitaxel, respectively. The cisplatin (40 mg/m2) or paclitaxel (80 mg/m2) was administered weekly, and phenoxodiol was administered by intravenous infusion at
'/>"/>

SOURCE Marshall Edwards Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014  eRelevance Corporation ( www.erelevancecorp.com ), ... that it has completed integration with Nextech, a ... Surgery and Dermatology practices. "Integration allows ... healthcare practices using Nextech," stated Bob Fabbio ... information from the EMR we are able to ...
(Date:8/21/2014)... , Aug. 21, 2014 The spinal column ... the human body. Signals carried to and from the brain ... skills and nervous system. Injury or ailment here can be ... with a loss of control over their body. Though back ... a person,s life, there are more options available to make ...
(Date:8/21/2014)... -- Publicis Groupe customer engagement agency Rosetta today ... Industry Group Leader, has been featured in the 2014 ... people in the life-sciences industry. Those chosen for this ... technology, creativity, strategy and medicine. Hartley ... its leading Rosetta Consulting practice. In 2012, she was ...
Breaking Medicine Technology:eRelevance Corporation Integrates with Nextech Electronic Medical Records 2Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2Shannon Hartley Shines in PharmaVOICE 100 2
... ROSA, Calif. , Feb. 16 Osseon Therapeutics Inc. ... Europe . The procedures were performed in Milan, Italy . ... independent medical device distributor in Europe , Osseoplasty cases are ... United Kingdom , Germany and Spain . , ...
... N.J. , Feb. 16 IntegriChain, Inc., ... the launch of its new DNA: Dynamic NextGen ... helps pharmaceutical manufacturers unlock the value of Direct Data ... Data includes those data assets typically provided to ...
Cached Medicine Technology:Osseon Launches in Europe 2IntegriChain Launches DNA: Dynamic NextGen Analytics(TM) Platform 2IntegriChain Launches DNA: Dynamic NextGen Analytics(TM) Platform 3
(Date:8/21/2014)... August 21, 2014 A new study ... 63% increase in disability associated with speech problems from ... more than 15% increase in disability associated with hearing ... for rising numbers of children who are experiencing communication ... (ASHA). , On a broader level, the new ...
(Date:8/21/2014)... WA (PRWEB) August 21, 2014 ... Mulanax at Eastlake Chiropractic and Massage Center ... the Center’s growing team. Rina Lang, LMP and ... a wide range of massage techniques, and have developed ... settings. This is particularly important in a clinical ...
(Date:8/21/2014)... woman is to focus on her body in terms ... viewing her as a complete human being with thoughts ... problem in the media, how does it affect individual ... Women Quarterly , a SAGE journal, finds that more ... higher incidents of sexual pressure and coercion., Researchers Laura ...
(Date:8/21/2014)... physicians in rural communities do not routinely screen ... Penn State medical and public health researchers. Rural ... limited resources if they seek help., "Rural health ... said Jennifer S. McCall-Hosenfeld, a primary care physician ... sciences, Penn State College of Medicine. "However, in ...
(Date:8/21/2014)... Aug. 21, 2014 Researchers in the United Kingdom ... can quickly and accurately diagnose a number of rare ... study published online today in Ophthalmology , ... Using a single test, doctors were able to tailor ... mutations reducing the time and money spent on diagnosis ...
Breaking Medicine News(10 mins):Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 2Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 3Health News:Seattle’s Eastlake Chiropractic and Massage Center Is Pleased to Introduce Rina Lang and Mike Larios as New Members of Its Massage Therapy Team 2Health News:Seattle’s Eastlake Chiropractic and Massage Center Is Pleased to Introduce Rina Lang and Mike Larios as New Members of Its Massage Therapy Team 3Health News:Objectification in romantic relationships related to sexual pressure and coercion 2Health News:Primary care physicians can be critical resource for abused women in rural areas 2Health News:New DNA test for diagnosing diseases linked to childhood blindness 2
... Gengraine Technologies (Avesthagen) has tied up //with Denmark's ... Fund for Developing Countries (IFU) for osteoporosis research. ... joint venture called Avesta Nordic Research Pvt. Ltd ... and the Danish research organization had invested the ...
... the University of Buffalo, has found that Post-menopausal// women has ... reported in the Journal of Periodontology, which was conducted in ... The results showed 57.5% of the women in the study ... cause of tooth loss in Post-menopausal women, as studies has ...
... population of 35 million of whom two million people// have ... from HIV infections an estimated 12% of the country’s children ... ,Tanzania has planned to provide free anti-retroviral drugs ... a period of five years. This year 44,000 patients in ...
... largest state of India, registers its win against polio as the ... the 1242 reported in the year 2002. , ,UNICEF, and ... of the country are leading the war against polio in India. ... around 1600 were from India alone, and 1242 cases were registered ...
... Club Worldwide, //an organization that supports cancer patients., ,According ... have cancer, or when their parents or siblings have the ... for support." , ,"Gilda's Club is one of those ... so I am very happy to make this gift to ...
... New knowledge about the hormonal signals like peptide signals ... processing in the brain along with the conventional neurotransmitters., ... Edinburgh report that hypothalamic neurons use the chemical signals ... peptides when are released within the brain, control different ...
Cached Medicine News:Health News:Indian And Danish Research Agencies To Work Together For Osteoporosis, 2Health News:Post-Menopausal Status May Cause Tooth Decay 2Health News:Intense Fight Against Polio In India Gets Results 2Health News:Britney Spears Donates $50 000 To Support Cancer Patients 2Health News:Britney Spears Donates $50 000 To Support Cancer Patients 3
DSL-10-49200 is a rapid, direct enzyme immunoassay (EIA) kit that provides materials for the quantitative measurement of testosterone in serum. This kit requires no sample extraction or pretreatment...
RIA kit for the quantitative determination of autoantibodies to steroid 21-hydroxylase (21-OH) in serum....
... volume for use with 4, 8, or 12 ... withdrawal of nearly all of the solution. Corners ... Made of natural virgin polystyrene containing no regrinds. ... by irradiation. Dimensions: 78 mm W x 152 ...
... Increased volume for use with 4, ... and V-shaped bottom permits withdrawal of nearly ... lips to dispose of excess solution. Made ... Non-sterile. Dimensions: 78 mm W x 152 ...
Medicine Products: